Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2